Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
35 hedge funds and large institutions have $31.1M invested in Genocea Biosciences, Inc. in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 3 closing their positions.
4,614% more call options, than puts
Call options by funds: $3.35M | Put options by funds: $71K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
30% more capital invested
Capital invested by funds: $23.9M → $31.1M (+$7.27M)
6% more funds holding
Funds holding: 33 → 35 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$272K |
| 2 |
Millennium Management
New York
|
+$158K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$105K |
| 4 |
BlackRock
New York
|
+$104K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$43.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$725K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$332K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$249K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$189K |
| 5 |
Renaissance Technologies
New York
|
-$87.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Commonwealth Equity Services
Waltham,
Massachusetts
| $32K | – | – | – |
|
27
Wells Fargo
San Francisco,
California
| $23K | -$16.6K | -7,214 | -41% |
|
28
Bank of America
Charlotte,
North Carolina
| $14K | +$2.08K | +901 | +17% |
|
|
AA
29
AlphaMark Advisors
Ft. Wright,
Kentucky
| $13K | +$1.38K | +600 | +12% |
|
30
Morgan Stanley
New York
| $10K | +$4.07K | +1,769 | +62% |
|
31
Citigroup
New York
| $3K | – | – | – |
|
|
AWA
32
Artemis Wealth Advisors
New York
| $2.62K | – | – | – |
|
33
Acadian Asset Management
Boston,
Massachusetts
| – | -$19K | -10,878 | Closed |
|
34
Victory Capital Management
San Antonio,
Texas
| – | -$12K | -6,512 | Closed |
|
35
JP Morgan Chase
New York
| – | +$23 | +10 | New |
|
36
Barclays
London,
United Kingdom
| – | +$129 | +56 | New |
|
37
Simplex Trading
Chicago,
Illinois
| – | +$543 | +236 | New |
|
GNCA Hedge Fund Activity: Q2 2020 in Review
35 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q2 2020, worth a combined $31.1M — up 30% from $23.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GNCA positions and 3 closed out — a net gain of 2 holders — while 12 added to existing stakes and 9 trimmed.
The largest buyer was Squarepoint, adding an estimated $272K. The largest seller was Sabby Management, cutting an estimated $725K.
- 35 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q2 2020, up from 33 in Q1 2020.
- Funds reported $31.1M of Genocea Biosciences, Inc. stock for Q2 2020, up 30% quarter-over-quarter.
- 5 funds opened new Genocea Biosciences, Inc. positions in Q2 2020 and 3 closed out, a net change of +2 holders.
- The largest Genocea Biosciences, Inc. buyer in Q2 2020 was Squarepoint, an estimated $272K added.
- The largest Genocea Biosciences, Inc. seller in Q2 2020 was Sabby Management, an estimated $725K sold.
Based on aggregated 13F filings for Q2 2020.